Texas Biotechnology Corp. of Houston said it elected David B.McWilliams as president and chief executive officer. TBC, whichis focused on endothelium research, is developing proprietarymolecules to treat various cardiovascular diseases, includingarterial restenosis and hypertension.

(BioWorld mistakenly reported on Wednesday that McWilliamswas joining another Texas-based biotechnology company.)

McWilliams previously held the same positions at Zonagen Inc.of Houston, which is developing recombinant contraceptivevaccines for animal and human health care. Before Zonagen, hewas president and CEO of Kallestad Diagnostics, a division ofErbamont N.V. and held management positions at AbbottLaboratories.

At TBC, McWilliams replaces David W. Ortlieb, a TBC founderwho resigned for family-related reasons, the company said.

(c) 1997 American Health Consultants. All rights reserved.